Reuters logo
BRIEF- Tanvex Biopharma unit to commence phase III clinical trial for TX05(Herceptin Biosimilar)
September 28, 2017 / 7:37 AM / 25 days ago

BRIEF- Tanvex Biopharma unit to commence phase III clinical trial for TX05(Herceptin Biosimilar)

Sept 28 (Reuters) - Tanvex Biopharma Inc :

* Says its unit gets approval from FDA to commence phase III clinical trial for TX05(Herceptin Biosimilar), which is used for treatment of mastocarcinoma

Source text in Chinese: goo.gl/MCm6xA

Further company coverage: (Beijing Headline News)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below